We have used the bone marrow micronucleus assay (BMMN) as a measure of clastogenicity, in response to etoposide exposure in murine bone marrow. Oral delivery of etoposide resulted in a reduced number of micronucleated polychromatic erythrocytes (MPE) relative to the same dose delivered intraperitoneally (P Ͻ 0.001). Daily fractionation of the oral schedule of etoposide led to a more than six-fold increase in cumulative MPE frequency over that observed with the same total, unfractionated dose, with the potency of the response increasing with serial exposure (r = 0.79). Retrovirally-mediated expression of MDR1 in murine bone marrow resulted in partial protection against the clastogenic activity of etoposide relative to mock transduced control mice. The model system developed has indicated a variety of factors able to influence the genotoxicity of etoposide. It should now be possible to further exploit this model in order to define other factors governing haemopoietic sensitivity to etoposide.
Introduction
The epipodophyllotoxins etoposide and teniposide are chemotherapeutic agents that are widely used in the management of solid tumours and haematological malignancies. 1 Both compounds form cleavable complexes with DNA topoisomerase II and therefore induce double-stranded DNA breaks which, if unrepaired, are responsible for cell death both in tumour and in dose-limiting tissues such as the bone marrow. [2] [3] [4] [5] [6] Persistent DNA damage in surviving cells is implicated in the genesis of a therapy-related secondary leukaemia (tAML) which is characterised by a translocation involving the MLL1 gene at 11q23. 7 Although tAML is a relatively rare event there is a significant body of evidence indicating that the risk of developing secondary leukaemia increases with the frequency of administration and cumulative exposure to these drugs. [8] [9] [10] [11] [12] [13] The frequency of tAML appears to rise after cumulative doses in excess of 2000 mg/m 2, [8] [9] [10] [11] and other studies, most notably in childhood leukaemia, have indicated that twice weekly or weekly administration of etoposide is associated with a cumulative risk of tAML approaching 12%. 13 While these retrospective studies demonstrate the association between etoposide exposure and tAML, they are unable to elucidate and predict additional factors which may influence the frequency of persistent DNA damage. This may include effects of other DNA damaging agents such as cisplatin 14, 15 and alkylating agents, 12, 16 anti-metabolites, 13 ,17 growth factors 18 and therapeutic manoeuvres such as genetic manipu-lation of drug resistance which aim to increase bone marrow tolerance to chemotherapy. 19 The latter two factors may be particularly important, as there may be a correlation between reducing acute cytotoxicity and promoting survival of genetically damaged cells. To investigate this concept further we have established a murine model in which a single genotoxic endpoint can be quantified in the context of different treatment strategies aimed at improving the therapeutic index of etoposide. Thus it is possible to relate dose, schedule and other factors including the expression of drug resistance functions such as MDR1, to a defined measure of DNA damage.
A number of assays for genotoxicity is available and following initial investigation the bone marrow micronucleus (BMMN) assay was chosen as an appropriate measure of DNA damage. 20 This assay detects clastogenic damage which persists after one full cycle of erythrocyte replication (Figure 1 )
Figure 1
The BMMN assay detects clastogenic activity in the erythropoietic lineage of the haemopoietic compartment in the form of MPE. PE lack a nucleus and therefore MN are easily detectable in these cells. The PE and MPE mature into normocytes, which may senesce in the bone marrow or migrate into the peripheral blood along with the immature MPE and PCE.
and is considered to be a good surrogate marker for the carcinogenic potential of any genotoxin. The current study describes the sensitivity of the BMMN assay following etoposide exposure, and considers the influence of dose, route and schedule of etoposide administration on micronucleus induction. Furthermore, given the current interest in protecting bone marrow from the acute cytotoxic effects of chemotherapy by overexpression of MDR1, 21 we have used the mouse model to investigate the impact of this strategy on etoposide-induced micronucleus frequency.
Materials and methods

Chemicals
A clinical preparation of etoposide was purchased from Bristol Myers (Hounslow, UK) and contained etoposide at a concentration of 20 mg/ml, as well as citric acid (2 mg/ml), polyethylene glycol 300 (650 mg/ml), benzyl alcohol (30 mg/ml), Tween 80 (80 mg/ml) and ethanol (30.5% v/v). Etoposide was diluted to the required concentrations (0.1-1.0 mg/ml) in physiological saline and was prepared immediately before administration to animals.
Mice
Male and female B6D2F1 mice aged 8 to 10 weeks old were obtained from the Paterson Institute breeding colony. All experimental procedures were performed in accordance with the Animals (Scientific Procedures) Act (1986).
Bone marrow micronucleus assay
Groups of mice were treated with drug and were sacrificed by cervical dislocation 24 h after treatment. The bone marrow from one femur of each mouse was flushed into 1 ml of foetal calf serum. Smears were prepared on glass microscope slides, were stained with acridine orange as described previously 22 and assessed for micronucleated polychromatic erythrocyte (MPE) frequency amongst 2000 polychromatic erythrocytes (PCE). The ratio of PCE to normochromatic erythrocytes (NE) amongst 1000 cells was also analysed for each mouse as an indicator of the toxicity of etoposide to the erythroid compartment of the bone marrow.
The frequency of micronucleated peripheral blood reticulocytes was determined by smearing a drop of blood (removed via cardiac puncture) from the treated mice 48 h after drug administration and on to a pre-coated microscope slide under a coverslip. Cells were stained super vitally with acridine orange as previously described. 23 The slides were analysed for the frequency of micronucleated reticulocytes amongst 1000 reticulocytes (see Tables 1 and 2 for the dosing regimens employed).
Reconstitution of mice with MDR-1 transduced bone marrow
Bone marrow was harvested from both femurs of 100 male mice 48 h after treatment with 150 mg/kg of 5-fluorouracil (David Bull Laboratories, Warwick, UK) intravenously. The bone marrow cells were then cultured in prestimulation medium (DMEM supplemented with 20% foetal calf serum, 0.1% BSA, 2 mM glutamine, 200 U/ml recombinant human IL-6 (Sandoz, Basle, Switzerland)), 10 ng/ml recombinant murine IL-3 (R&D Systems, Abingdon, UK) and 100 ng/ml recombinant rat stem cell factor (Amgen, Thousand Oaks, CA, USA) for 48 h at 37°C. Bone marrow cell cultures were then overlaid on to amphotropic MDR-1 retroviral producers 24 or ␣-iduronidase producers 25 (mock transduction) for 48 h in the same medium with the addition of 5 g/ml polybrene. Bone marrow cells were harvested by gentle shaking of the culture flasks and after a wash in serum-free medium were injected into the tail vein of 100 female marrow ablated recipients (irradiated at 15 Gy using a 60 Co source over 16 h) at 5 × 10 6 cells/mouse. 26 After a period of 4-6 weeks the mice were entered into the BMMN assay.
Leukemia
Granulocyte-macrophage colony-forming unit plating
An aliquot of 10 5 bone marrow cells from pooled group samples, 4 weeks after transduction and transplantation was suspended in 0.5 ml of IMDM supplemented with 20% FCS, 10% BSA and 1% IL-3. Next, 0.5 ml of methylcellulose was added and the solution was mixed with a blunt-ended needle. The mixture was then plated into three wells of a 24-well microtitre plate which was then incubated at 37°C for 1 week in an atmosphere of 5% CO 2 , 5% O 2 , 90% N 2 . Colonies were picked into 50 l of K buffer (100 l 10 × PCR buffer, 900 l 0.5% Tween 20 and 5 l proteinase K (20 mg/ml)), flash frozen in liquid nitrogen and stored at −80°C prior to analysis by PCR for human MDR-1 and murine Y-chromosome DNA sequence.
Figure 2
The micronucleus frequency (bars) and polychromatic to normochromatic erythrocyte ratio (PCE:NE, line) in the bone marrow of male B6D2F1 mice treated with increasing i.p. doses of etoposide (n = 5). The number of MPE amongst 2000 PCE and the ratio of PCE:NE among 1000 cells were counted. Results represent the means and standard errors of the individual animal data. These data were reproduced in a second experiment employing the same number of mice and dosing regimen (data not shown).
PCR to detect human MDR-1 and murine Ychromosome sequence
PCR of human MDR-1 cDNA was carried out using primers that span a 523 bp fragment of DNA (sense, 5Ј AGA TCA ACT CGT AGG AGT GTC 3Ј, antisense, 5Ј GTT TCT GTA TGG TAC CTG CAA 3Ј) with 35 cycles of 94°C for 1 min, 59°C for 1 min and 72°C for 1 min followed by 5 min at 72°C. As a control for amplifiable DNA in GM-CFC colonies, PCR was carried out using primers specific for regions of murine Ychromosome DNA according to a standard protocol. 27 
Statistical analysis
Results were analysed for statistical significance using the Student's t-test except for the experiment analysing both 24 h bone marrow and 48 h bone marrow and blood, where results were analysed by Spearman's correlation.
Results
Sensitivity of the bone marrow micronucleus assay to etoposide
Etoposide causes a dose-dependent suppression of bone marrow function. This is manifest in the erythrocyte compartment as a block in production of polychromatic erythrocytes and hence depression in the PCE:NE ratio (Figure 2 ). For the purpose of the BMMN assay a PCE:NE ratio of Ͼ1 indicates a level of toxicity above which the dose dependence of micronucleus induction is lost due to the impact of toxicity on polychromatic erythrocyte production. 20 When etoposide was administered via the intraperitoneal (i.p.) route, a PCE:NE ratio of Ͼ1 was reached at doses between 0.5 and 1 mg/kg. This is consistent with the observed rise in MPE frequency at etoposide doses up to 1 mg/kg. For this reason, 1 mg/kg was selected as the reference dose for micronucleus induction in subsequent studies involving i.p. administration of etoposide.
Determination of the effect of route of administration on etoposide-induced micronucleus formation
The route of administration of etoposide had a profound effect on the frequency of micronucleus induction. As expected, 1 mg/kg of etoposide administered i.p., produced a potent response and at a level consistent with those described before ( Figure 3) . Oral (p.o.) administration of 1 mg/kg etoposide resulted in a major reduction in the number of micronuclei observed (P Ͻ 0.001) compared to the same dose given by the i.p. route. This difference is not explained by toxicity as the PCE:NE ratio following either route of exposure remained above 1 (Table 3) 
Determination of the effect of fractionated schedule on etoposide-induced micronucleus induction
To determine whether the micronucleus assay can discriminate between different schedules of etoposide, animals were administered drug to a maximal cumulative oral dose of 10 mg/kg in varying daily fractions (see Figure 4) . Administration of a single dose of 10 mg/kg in this experiment produced a comparable frequency of MPE to that demonstrated in Figure  3 . However, fractionating the dose to 2 × 5 mg/kg and 4 × 2.5 mg/kg led to a significant (Ͼ two-fold) elevation (P Ͻ 0.01) in the frequency of MPE measured 24 h after delivery of the final dose of etoposide. Further fractionation of the dose did not show any significant increase in MPE over a single dose of 10 mg/kg. However, the number of MPE seen 24 h after the last administration of 10 × 1 mg/kg etoposide was significantly higher (P Ͻ 0.05) than that seen following a single dose of 1 mg/kg of this agent ( Figure 3 ). Possible explanations for this result might include persistence of MPE in the bone marrow over the time course of the experiment or some priming event which leads to increased sensitivity to subsequent doses of drug. To try to distinguish between these two possibilities we determined whether MPE accumulated in bone marrow or peripheral blood at serial time points in the 4 × 2.5 mg/kg schedule, 48 h following the last exposure to etoposide. The effect of treating mice with 1, 2, 3 or 4 consecutive doses of 2.5 mg/kg of etoposide are shown in Figure 5 . With each serial exposure there was a trend towards increasing MPE frequency at 24 h after treatment (r = 0.79, P Ͻ 0.001) although the differences between consecutive treatments were not statistically significant (P Ͻ 0.05). There was no evidence of persistence of MPE in the bone marrow nor that micron-
Figure 4
The frequency of MPE in the bone marrow of mice 24 h following administration of the final dose of etoposide given p.o.
Leukemia
Figure 5
The frequency of MPE in the bone marrow of mice treated with the indicated doses of etoposide 24 (solid bars) and 48 h (open bars) following administration of the final dose in the bone marrow and 48 h following the final dose in peripheral blood (hatched bars). ucleated reticulocytes migrated into the peripheral blood 48 h after the last dose, indicating that the increased frequency of MPE seen with dose fractionation was not due to accumulation of these cells. Calculation of the total number of MPE seen over the experiment indicated that not only did dose fractionation lead to an increase in genotoxic damage detectable 24 h following the final dose of etoposide administered, but the cumulative damage over the dosing period was more than six times that resulting from a single dose of 10 mg/kg.
Influence of overexpression of MDR1 on micronucleus induction following etoposide exposure
In order to investigate the influence of MDR1 overexpression on MPE induction by etoposide, bone marrow from male mice were transduced with a retrovirus containing either the human MDR1 cDNA (experimental) or an irrelevant control cDNA (mock transduced). The cells were then transplanted back into female myeloablated recipients. Analysis of colony-forming cells from recipient mice indicated that a transduction efficiency of around 18% (9/50 PCR-positive colonies) had been achieved, and subsequent micronucleus assay demonstrated that MDR1 transduction conferred a statistically significant protection (P Ͻ 0.05) against micronucleus induction by etoposide (Figures 6 and 7) . 
Discussion
Although etoposide is widely recognised as a powerful leukaemogen, [7] [8] [9] [10] [11] [12] [13] it remains an important drug in cancer therapy. A number of factors increase the risk of secondary malignancy and these include cumulative exposure to drug and rapid scheduling of etoposide pulses. [8] [9] [10] [11] [12] [13] A recent review of the modes of etoposide administration in UK paediatric practice revealed 21 different schedules in multiple drug combinations. 28 The most common method of drug delivery is intravenously at doses of 360-450 mg/m 2 fractionated over 3 days, and repeated every 3 weeks, although protracted oral fractionated schedules, eg 50 mg/m 2 daily for 21 days have also been used extensively. The latter schedule is a well tolerated outpatient treatment, is associated with little haematological toxicity and, because of the maintenance of significant serum levels of drug over many days, may have increased efficacy. 29, 30 Most reports of etoposide-associated secondary leukaemia have followed pulsed intravenous therapy. 13 Recently, concern has been expressed over orally administered etoposide, although in the report of this work patients have been heavily pre-treated with other DNA damaging agents, thus making it difficult to determine the specific contribution of etoposide. 31 The influence of such confounding variables on cancer risk are difficult to assess and consequently this study set out to establish a model in which the interaction of such factors could be studied. The initial objectives were to identify a surrogate endpoint for relevant DNA damage following etoposide exposure (DNA strand breaks/translocation events), which was also sufficiently sensitive to detect damage over a clinically relevant dose range (1.7-6.7 mg/kg/day). 28 Following initial assessment of three different assays, the 'comet assay', 32 the 'MutaMouse model' 33 and the BMMN assay, 20 we concentrated on the latter since it provided a reliable and reproducible measure of DNA damage at clinically-relevant dose ranges.
A number of studies have shown that the BMMN assay is a robust measure of the clastogenic activity of a variety of compounds, including etoposide. 34, 35 Moreover, given that micronuclei result from the lag of chromosomal fragments on the mitotic spindle, induction of these reflects damage that persists through at least one full cycle of DNA synthesis and repair. Our results demonstrate that the assay is very sensitive to the effects of etoposide exposure, with a significant induction of MPE at doses as low as 0.1 mg/kg i.p. A dose-dependent rise in MPE induction was seen up to 1 mg/kg i.p. after which the balance between sublethal and cytotoxic events was shifted towards bone marrow toxicity (as evidenced by a reduction in the ratio of PE/NE to below one). The dose dependency of MPE induction was also demonstrated for the oral route of exposure, although neither maximal MPE induction nor toxicity were demonstrated. The explanation for this observation may rest in part with the differences in bio-availability of etoposide following oral and i.p. administration, as absorption of orally delivered etoposide may be as little as 17% of the administered dose. 36 Thus the route of drug delivery is an important factor in the routine assessment of druginduced clastogenicity using the BMMN assay, although for a specified route of exposure this is a relatively sensitive and consistent marker of DNA damage.
Given the apparent importance of schedule on the risk of therapy-induced leukaemia, we investigated if the BMMN assay was able to detect different levels of DNA damage following fractionated delivery of etoposide. An increased level of MPE induction has been reported following fractionated delivery of other drugs such as 1-␤-D-arabinofuranosyl cytosine (Ara-C) or methotrexate (MTX). 37 For the purpose of this study etoposide was delivered orally as this route has found increasing favour in clinical practice and is administered as a highly fractionated schedule (i.e. twice daily over 21 consecutive days).
Two conclusions can be drawn regarding the impact of fractionating the dose. Firstly, as for a single pulse of etoposide administration there is a dose-dependent rise in MPE induction measured 24 h after the last dose in any schedule unless bone marrow toxicity is seen. The dose dependency of fraction size is most clearly seen for the schedules of 10 × 1 mg, 8 × 1.25 mg and 4 × 2.5 mg where the PCE:NE ratio remains above one. Therefore it is not unreasonable to conclude that daily fractionation of etoposide administration is more clastogenic than a single high dose administration, and through survival of sublethally damaged cells is more likely to lead to the genesis of a secondary leukaemia. However, this is unlikely to be a simple relationship. Figure 5 illustrates that each administered fraction engenders a clastogenic response and that the response increases with sequential fractions. Thus the overall risk of persistent generating DNA damage must relate to the cumulative potency of the micronucleus response. Hyashi et al 38 accounted for the effect of cumulative exposure to drug by a model whereby MPE resulting from a previous dose remain in the bone marrow 48 h after administration and are detected along with those caused by a subsequent dose of agent resulting in an accumulation of MPE. This model was applied to a number different compounds and held true for some, although not for all agents tested. 38 Such a model cannot, however, be used to explain the increase in MPE as a result of exposure to multiple doses of etoposide, as the number of MPE at 48 h following the last dose of any series drops to background levels. For these same reasons the increased clastogenicity of subsequent doses cannot be easily explained by the persistence of occult DNA damage, which is then manifest as micronuclei following progression of cells through cycle. Were this the case, significant levels of MPE would be expected at 48 h following the last dose of etoposide in any series. Given that our data cannot be reconciled by a model where persistence and accumulation of MPE occurs during the dosing period, this points to an effect of etoposide administration which leads to sensitisation of the bone marrow to subsequent doses of this agent. A number of possibilities seem worthy of consideration. Firstly, that the etoposide-induced damage leads to increased cycling in the target compartment for micronucleus induction (the erythroid lineage). 39 If etoposide induces cells into cycle, then this may in turn result in a greater number of cells undergoing division in the presence of this clastogen and thus displaying the results of drug-induced injury. Another explanation for the observed effect might be that treatment with etoposide increases topoisomerase II levels in cells. 40 If this were the case, etoposide would be able to interact with more enzyme, resulting in higher levels of DNA strand breakage within target cells, and thus result in a higher incidence of MPE. Alternatively, it is possible that some element of long-term genomic instability occurs, similar to that seen following ␣-radiation damage to bone marrow. 41 Further experimentation will obviously be required to determine whether any of these mechanisms contribute to the observed effects.
Notwithstanding the mechanism of schedule-dependent exacerbation of etoposide-induced genotoxic damage to bone marrow, it is clear that some schedules are likely to be more genotoxic than others and that this is likely to reflect the clinical impact of etoposide administration. The model described here provides a relatively robust means of determining the impact of etoposide scheduling on the bone marrow compartment. Thus it may be possible, using this model, to derive a protocol for etoposide administration/scheduling that will achieve maximum tumour kill with minimum adverse effects on bone marrow.
Alternatively it may be the case that genotoxicity in bone marrow will always mirror tumour kill. If so, an alternative means of minimising bone marrow toxicity will be required. One alternative to modifying the dose/scheduling of etoposide to ameliorate long-term effects in bone marrow might be to modify the sensitivity of this tissue to etoposide. The MDR-1 gene product is known to confer resistance to the cytotoxic effects of etoposide and related agents by acting as a membrane pump that expels drug from cells, thus effectively lowering the concentration of active agent in these cells. 42 Whilst this undoubtedly leads to increased survival of cells, the effects on other endpoints of genotoxic damage are undocumented. In particular, one worry is that expression of MDR-1 in bone marrow cells which do not normally express this protein might lead to the increased survival of cells carrying sublethal, but potentially mutagenic and carcinogenic damage. 19 Our data, however, show a clear protective effect against the clastogenic activity of etoposide conferred by transfer of the human MDR-1 gene into bone marrow. This first ever demonstration of protection against clastogenicity by transfer and expression of the human MDR1 gene suggests that it may also be possible to reduce the mutagenic and potentially carcinoLeukemia genic effects of etoposide exposure using this approach. In this scenario, it may be the case that the exact nature of the scheduling of etoposide will become less important in terms of reducing the development of iatrogenic haemopoietic tumours and more emphasis may be put on maximising tumour kill.
